AstraZeneca posts Phase III baxdrostat hypertension results; registers new myeloma CAR-T trial
BaxHTN trial completed with results posted this week, while AstraZeneca also filed a new Phase III CAR-T study in transplant-eligible myeloma patients.
AstraZeneca had two notable regulatory registry updates this week, one reporting completed Phase III results and one registering a new large trial.
- **Baxdrostat (CIN-107), Phase III, uncontrolled and resistant hypertension**: The "BaxHTN" study is now completed, with results first posted on 2026-07-30. The trial evaluated 1 or 2 mg baxdrostat versus placebo, administered once daily, for reducing systolic blood pressure in about 720 participants with uncontrolled hypertension on a stable two-drug regimen or resistant hypertension on three or more antihypertensive agents.1 Actual enrollment reached 796 participants.1
- **AZD0120, Phase III, newly diagnosed transplant-eligible multiple myeloma**: The "DURGA-6" trial is not yet recruiting, with an estimated start of 2026-08-25. The study will compare AZD0120, a dual BCMA/CD19-targeting CAR-T therapy, with autologous stem cell transplant, measuring progression-free survival and MRD-negative complete response rate at 9 months.2 Estimated enrollment is 750 participants.2
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.